文献速递血栓与止血

Concizumab用于伴抑制物血友病的长期疗效与安全性:3期explorer7研究结果

Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study.
PubMed 文献 · Blood Adv · 2026-01-01

explorer7研究评估了抗TFPI单抗concizumab在伴抑制物血友病A或B患者中的长期疗效与安全性。56周截断时,接受concizumab预防治疗患者的中位ABR为0.8,与32周截断时的低出血率一致。Concizumab及游离TFPI浓度随时间保持稳定,未报告新的安全性问题。

要点

  • 伴抑制物血友病患者接受concizumab预防治疗,56周中位ABR为0.8。
  • 长期疗效与安全性结果与32周截断结果一致。
  • Concizumab和游离TFPI浓度随时间保持稳定,无新安全性问题。

核心结论

  • 伴抑制物血友病A或B患者接受concizumab预防治疗≥1年的疗效与安全性结果与32周截断结果一致。

研究设计与样本

  • 3期explorer7研究纳入133例≥12岁男性伴抑制物血友病患者,其中血友病A 80例、血友病B 53例。
  • 患者随机1:2分配至无预防治疗组或concizumab预防治疗组,或非随机分配至concizumab预防治疗组。
  • 无预防治疗组患者在治疗≥24周后可转为concizumab预防治疗,共13例转换。
  • 最终114例接受concizumab预防治疗,19例随机分配至无预防治疗组。

主要发现

  • 56周截断时,接受concizumab预防治疗患者治疗性自发性及创伤性出血事件的中位ABR为0.8(IQR 0.0-3.2)。
  • 32周截断时中位ABR为0.0(IQR 0.0-3.3),56周结果与之保持一致。
  • Concizumab和游离TFPI浓度随时间保持稳定,未报告新的安全性问题。

临床怎么用

  • concizumab每日一次皮下预防治疗可用于伴抑制物血友病A或B患者,长期出血控制与短期结果一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody intended for once-daily subcutaneous prophylactic treatment for people with hemophilia A or B with and without inhibitors. Results from the phase 3 explorer7 study confirmed superiority of concizumab prophylaxis over no prophylaxis in reducing the annualized bleeding rate (ABR) in people with hemophilia A or B with inhibitors (HAwI/HBwI). Male patients aged ≥12 years were randomized 1:2 to no prophylaxis (group 1) or concizumab prophylaxis (group 2), or nonrandomly allocated to concizumab prophylaxis (groups 3 and 4). After ≥24 weeks of treatment, patients in group 1 could switch to concizumab prophylaxis. At the 56-week cutoff (defined as when all patients in groups 2-4 had completed the visit at 56 weeks or permanently discontinued treatment), bleed-related efficacy, pharmacokinetics and pharmacodynamics, and safety were assessed. Of the 133 patients enrolled (HAwI, n = 80; HBwI, n = 53), 114 received concizumab prophylaxis (groups 2-4) and 19 were randomized to no prophylaxis (group 1). After ≥24 weeks, 13 patients from group 1 switched to concizumab. Median ABR for treated spontaneous and traumatic bleeding episodes in patients receiving concizumab was 0.8 (interquartile range [IQR], 0.0-3.2) at the 56-week cutoff, consistent with the low bleeding rates (median ABR, 0.0; IQR, 0.0-3.3) at the 32-week cutoff. Concizumab and free-TFPI concentration remained stable over time. No new safety concerns were reported. Longer-term (≥1 year) efficacy and safety results of concizumab prophylaxis for HAwI/HBwI were consistent with the 32-week cutoff results in explorer7. This trial was registered at www.clinicaltrials.gov as #NCT04083781.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Mahlangu J, Boban A, Bruzelius M, et al. Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study. Blood Adv. 2026. PMID: 41499759. doi:10.1182/bloodadvances.2025018264

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。